Extracorporeal Filtration of Thermosensitive Liposomes

项目总结/摘要 该项目将开发一种设备，并在啮齿动物肿瘤模型中进行概念验证研究。该设备将 在靶向递送至肿瘤后从体循环中除去化疗剂阿霉素。 靶向递送通过将阿霉素递送至肿瘤区域的温度敏感性脂质体发生。通过 将肿瘤暴露于高温（40-42 ºC），药物局部释放并以高剂量被肿瘤吸收。 在热疗之后，任何剩余的药物将导致对非靶向组织的毒性，并且通过以下方式去除： 所提出的体外过滤装置具有去除药物量的实时定量。如果成功，这 将代表一种新的方法，以减少剂量限制性毒性，允许提供更高的化疗 剂量和/或减少毒性相关的副作用。

PROJECT SUMMARY/ABSTRACT This project will develop a device and perform proof-of-concept studies in a rodent tumor model. The device will remove the chemotherapy agent Doxorubicin from systemic circulation after targeted delivery to tumors. Targeted delivery occurs by temperature sensitive liposomes delivering Doxorubicin to tumor regions. By exposing tumors to hyperthermia (40-42 ºC), drug is locally released and taken up by tumors at high dose. Following hyperthermia, any remaining drug would result in toxicity to non-targeted tissue, and is removed by the proposed extracorporeal filter device with real-time quantification of removed drug amount. If successful, this would represent a novel approach to reduce dose-limiting toxicities, allowing delivery of higher chemotherapy dose and/or reducing toxicity related side effects.